Company Description
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States.
It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E.
Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996.
The company was incorporated in 1996 and is headquartered in Emeryville, California.
| Country | United States |
| Founded | 1996 |
| IPO Date | Feb 19, 2004 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 408 |
| CEO | Ryan Spencer |
Contact Details
Address: 2100 Powell Street, Suite 720 EmeryVille, California 94608 United States | |
| Phone | 510 848 5100 |
| Website | dynavax.com |
Stock Details
| Ticker Symbol | DVAX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001029142 |
| CUSIP Number | 268158201 |
| ISIN Number | US2681582019 |
| Employer ID | 33-0728374 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ryan Spencer | Chief Executive Officer and Director |
| David F. Novack | President and Chief Operating Officer |
| Dr. Robert Janssen M.D. | Chief Medical Officer and Senior Vice President of Clinical Development, Medical and Regulatory Affairs |
| Justin Burgess | Chief Accounting Officer and Controller |
| Jeff P. Coon | Senior Vice President and Chief Human Resources Officer |
| Paul Cox | Vice President of Investor Relations and Corporate Communications |
| John L. Slebir | Senior Vice President and General Counsel |
| Donn Casale | Senior Vice President and Chief Commercial Officer |
| Dr. Dong Yu | Senior Vice President of Vaccine Research |
| Eric Frings | Vice President, Site Head and MD for Dynavax GmbH |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 8-A12B | Registration of securities |
| Oct 29, 2024 | 8-K | Current Report |
| Oct 24, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 16, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |